Table 2. The sensitivity of serum miR-223-3p, AFP and combination in diagnosis of HCC according to tumor staging.
BCLC Staging | miR-223-3p (0.4) | AFP (20 ng/ml) | miR-223-3p and AFP |
---|---|---|---|
Stage 0, A (n = 21) | 13 (61.9) | 12 (57.1) | 18 (85.7) |
Stage B (n = 24) | 18 (75.0) | 15 (62.5) | 24 (100) |
Stage C,D (n = 25) | 25 (100) | 16 (64.0) | 25 (100) |
Data expressed as n (%)